A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS - Tabular View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS

This study has been completed.

Study NCT00002257. Last updated on June 23, 2005. Information provided by NIH AIDS Clinical Trials Information Service

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields
Brief Title ^†	A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS
Official Title ^†	A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS
Brief Summary	To compare the time to progression of CMV retinitis between oral ganciclovir and IV ganciclovir during 20 weeks of maintenance treatment. To compare the safety and tolerance of oral ganciclovir with IV ganciclovir therapy during 20 weeks of maintenance treatment. To describe the safety and tolerance of oral ganciclovir treatment when given concurrently with anti-retroviral treatment, e.g. zidovudine or ddI. To describe the survival of people with AIDS and CMV retinitis.
Detailed Description	Approximately 150 subjects with AIDS and newly diagnosed CMV retinitis will be enrolled in the study to achieve 120 randomized subjects. Eligible subjects will have CMV retinitis which has been diagnosed within one month of study entry by an ophthalmologist using indirect ophthalmoscopy. Subjects will be accrued by recruitment or referral. Anyone who volunteers for the study, meets the eligibility criteria, and signs an informed consent will be eligible for entry.
Study Phase
Study Type ^†	Interventional
Study Design ^†	Treatment, Placebo Control, Safety Study
Primary Outcome Measure ^†
Secondary Outcome Measure ^†
Condition ^†	Cytomegalovirus Retinitis HIV Infections
Intervention ^†	Drug: Ganciclovir
MEDLINE PMIDs
Links

Recruitment Information Fields
Recruitment Status ^†	Completed
Enrollment ^†	150
Start Date ^†
Completion Date
Eligibility Criteria ^†	Inclusion Criteria Patients must have the following: Confirmation of HIV infection by HIV-antibody testing, p24 antigen assay, or culture of HIV, or have diagnosis of AIDS by CDC criteria. CMV retinitis diagnosed within one month of study entry. Understand the nature of the study, agree to its provisions, and sign the informed consent approved by the appropriate institutional review board and Syntex. Exclusion Criteria Concurrent Medication: The following are excluded: Antimetabolites. Alkylating agents. Selected nucleoside analogs. Selected Cytokines. Patients with the following are excluded: Persistent diarrhea, nausea, or abdominal pain or other clinically significant GI symptoms or uncontrolled gastrointestinal disease. Diarrhea is defined as 3 or more unformed stools per day. Have ocular media opacities (corneal, lenticular, or vitreal) preventing ophthalmologic retinal assessment and photography. Have ocular conditions requiring immediate surgical correction (e.g. retinal tear or detachment). Require continuation of concomitant medications precluded by this protocol, e.g., antimetabolites, alkylating agents, selected nucleoside analogs, and selected cytokines and other medications listed in the protocol. History of hypersensitivity to acyclovir or ganciclovir. Dementia, decreased mentation or other encephalopathic signs and symptoms which would interfere with the ability of the subject to give informed consent or comply with the protocol. Prior Medication: The following are excluded: - Previous use of anti-cytomegalovirus drug (e.g., ganciclovir, foscarnet, FIAC, or CMV hyperimmune globulin) within one month of study entry.
Gender	Both
Ages	13 Years and older
Accepts Healthy Volunteers	No
Contacts ^††
Location Countries ^†	United States, Canada

Administrative Information Fields
NCT ID ^†	NCT00002257
Organization ID	059B
Secondary IDs ^††	ICM 1653
Study Sponsor ^†	Hoffmann-La Roche
Collaborators ^††
Investigators ^†
Information Provided By	NIH AIDS Clinical Trials Information Service
Verification Date	July 1992
First Received Date ^†	November 2, 1999
Last Updated Date	June 23, 2005

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.